Claims
- 1. Sulphonamide compound of the formula ##STR20## wherein R is hydrogen or lower alkyl;
- R.sub.1 is alkyl of up to 16 carbon atoms except when R is H, aryl having 6 to 14 carbon atoms, aralkyl with an alkyl moiety of up to 5 carbon atoms or aralkenyl with an alkenyl moiety of 2 or 3 carbon atoms, the aryl moiety of which in either case having 6 to 14 carbon atoms and being optionally substituted with one or more hydroxyl, fluorine, chlorine, bromine, trifluoromethyl, lower alkyl or alkoxy or by acetyl, carboxy or alkoxycarbonyl with 1-5 carbon atoms in the alkoxy moiety, radical;
- n is 1, 2 or 3; and
- W is a valence bond or a divalent aliphatic hydrocarbon linkage having up to 6 carbon atoms; and
- the physiologically acceptable salt, lower alkyl ester or amide of the WCOOH group of such compound wherein the amide component is selected from the group consisting of ammonia, p-aminobenzoic acid, beta-alanine; ethanolamine, 2-aminopropanol, alkylamine, dialkylamine, 4-alkylpiperazine, 4-aralkylpiperazine and 4-arylpiperazine.
- 2. Compound as claimed in claim 1 wherein R is hydrogen.
- 3. Compound as claimed in claim 1 wherein R is lower alkyl of up to 5 carbon atoms.
- 4. Compound as claimed in claim 1 wherein R.sub.1 is alkyl of up to 16 carbon atoms.
- 5. Compound as claimed in claim 1 wherein R.sub.1 is aryl of from 6 to 14 carbon atoms.
- 6. Compound as claimed in claim 1 wherein R.sub.1 is substituted aryl of from 6 to 14 carbon atoms, the substituent being selected from hydroxyl, halogen, alkyl, alkoxy, trifluoromethyl, carboxyl and acyl.
- 7. Compound as claimed in claim 1 wherein R.sub.1 is aralkyl with up to 5 carbon atoms in the alkyl moiety.
- 8. Compound as claimed in claim 1 wherein R.sub.1 is substituted aralkyl with up to 5 carbon atoms in the alkyl moiety wherein the aryl moiety is substituted by at least one of hydroxyl, fluorine, chlorine, bromine, trifluoromethyl, lower alkyl, lower alkoxy, acetyl, carboxy or alkoxycarbonyl with 1-5 carbon atoms in the alkoxy moiety, radical.
- 9. Compound as claimed in claim 1 wherein R.sub.1 is aralkenyl with from 2 or 3 carbon atoms in the alkenyl moiety.
- 10. Compound as claimed in claim 1 wherein R.sub.1 is substituted aralkenyl with from 2 or 3 carbon atoms in the alkenyl moiety wherein the aryl moiety is sibstituted by at least one of hydroxyl, fluorine, chlorine, bromine, trifluoromethyl, lower alkyl, lower alkoxy, acetyl, carboxy or alkoxycarbonyl with 1-5 carbon atoms in the alkoxy moiety, radical.
- 11. Compound as claimed in claim 1 wherein n is 1.
- 12. Compound as claimed in claim 1 wherein n is 2.
- 13. Compound as claimed in claim 1 wherein n is 3.
- 14. Compound as claimed in claim 1 wherein W is a valence bond.
- 15. Compound as claimed in claim 1 wherein W is a saturated divalent aliphatic hydrocarbon linkage.
- 16. Compound as claimed in claim 1 wherein W is alkenylene.
- 17. Compound as claimed in claim 1 wherein W is alkylene or alkenylene of up to 5 carbon atoms.
- 18. Compound as claimed in claim 1 wherein W is CH.sub.2.
- 19. Compound as claimed in claim 1 wherein W is CH.sub.2 CH.sub.2.
- 20. Compound as claimed in claim 1 wherein W is --C(CH.sub.3).sub.2 --.
- 21. Compound as claimed in claim 1 wherein R.sub.1 is phenyl.
- 22. Compound as claimed in claim 1 wherein R.sub.1 is phenyl substituted by 1 or 2 chlorine, fluorine, methoxy or trifluoromethyl groups.
- 23. Compound as claimed in claim 1 wherein W is alkylene of up to 3 carbon atoms and R is hydrogen.
- 24. Compound as claimed in claim 1 designated 4-[2-(4-toluenesulphoamido)-ethyl]-phenylacetic acid.
- 25. Compound as claimed in claim 1 designated 3-[4-(2-benzenesulphonamidoethyl)-phenyl]-propionic acid.
- 26. Compound as claimed in claim 1 designated 4-(2-benzenesulphonamidoethyl)-phenylacetic acid.
- 27. Compound as claimed in claim 1 designated 4-(3-benzenesulphonamidopropyl)-phenylacetic acid.
- 28. Compound as claimed in claim 1 designated 3-{4-[2-(2,5-dichlorobenzenesulphonamido)-ethyl]-phenyl}-propionic acid.
- 29. Method for inhibiting thrombocyte aggregation in an afflicted host, which method comprises administering to such host effective amounts of a sulphonamide compound of the formula ##STR21## wherein R is hydrogen or lower alkyl;
- R.sub.1 is alkyl of up to 16 carbon atoms, aryl of 6 to 14 carbon atoms, aralkyl with an alkyl moiety of up to 5 carbon atoms or aralkenyl with an alkenyl moiety of 2 to 3 carbon atoms the aryl moiety of which in either case having 6 to 14 carbon atoms and being optionally substituted with one or more hydroxyl, fluorine, chlorine, bromine, trifluoromethyl, lower alkyl or alkoxy or by acetyl, carboxy or alkoxycarbonyl with 1 to 5 atoms in the alkoxy moiety, radical;
- n is 1, 2 or 3; and
- W is a valence bond or a divalent aliphatic hydrocarbon linkage, and
- the physiologically acceptable salt, lower alkyl ester or amide of the WCOOH group of such compound wherein the amide component is selected from the group consisting of ammonia, p-aminobenzoic acid, beta-alanine; ethanolamine, 2-aminopropanol, alkylamine, dialkylamine, 4-alkylpiperazine, 4-aralkylpiperazine and 4-arylpiperazine.
- 30. Method as claimed in claim 29 wherein said sulphonamide compound is selected from
- 4-[2-(4-toluenesulphoamido)-ethylphenylacetic acid;
- 3-[4-(2-benzenesulphonamidoethyl)-phenyl]-propionic acid;
- 4-(2-benzenesulphonamidoethyl)-phenylacetic acid;
- 4-(3-benzenesulphonamidopropyl)-phenylacetic acid; and
- 3-{4-[2-(2,5-dichlorobenzenesulphonamido)-ethyl]-phenyl}-propionic acid.
- 31. Composition for depressing lipids, and inhibiting thrombocyte aggregation, which composition comprises a pharmacologically acceptable carrier and, in effective amounts, a sulphonamide compound of the formula ##STR22## wherein R is hydrogen or lower alkyl;
- R.sub.1 is alkyl of up to 16 carbon atoms, aryl of 6 to 14 carbon atoms or aralkenyl with an alkenyl moiety of 2 to 3 carbon atoms the aryl moiety of which in either case having 6 to 14 carbon atoms and being optionally substituted with one or more hydroxyl, fluorine, chlorine, bromine, trifluoromethyl, lower alkyl or alkoxy or by acetyl lower alkanyl, carboxy or alkoxycarbonyl with 1 to 5 carbon atoms in the alkoxy moiety, radical;
- n is 1, 2 or 3; and
- W is a valence bond or a divalent aliphatic hydrocarbon linkage, and
- the physiologically acceptable salt, lower alkyl ester or amide of the WCOOH group of such compound wherein the amide component is selected from the group consisting of ammonia, p-aminobenzoic acid, beta-alanine; ethanolamine, 2-aminopropanol, alkylamine, dialkylamine, 4-alkylpiperazine, 4-aralkylpiperazine and 4-arylpiperazine.
- 32. Method for depressing lipids in an afflicted host, which method comprises administering to such host effective amounts of a sulphonamide compound of the formula ##STR23## wherein R is hydrogen or lower alkyl;
- R.sub.1 is alkyl of up to 16 carbon atoms, aryl of 6 to 14 carbon atoms or aralkenyl with an alkenyl moiety of 2 to 3 carbon atoms the aryl moiety of which in either case having 6 to 14 carbon atoms and being optionally substituted with one or more hydroxyl, fluorine, chlorine, bromine, trifluoromethyl, lower alkyl or alkoxy or by acetyl lower alkanyl, carboxy or alkoxycarbonyl with 1 to 5 carbon atoms in the alkoxy moiety, radical;
- n is 1, 2 or 3; and
- W is a valence bond or a divalent aliphatic hydrocarbon linkage, and
- the physiologically acceptable salt, lower alkyl ester or amide of the WCOOH group of such compound wherein the amide component is selected from the group consisting of ammonia, p-aminobenzoic acid, beta-alanine; ethanolamine, 2-aminopropanol, alkylamine, dialkylamine, 4-alkylpiperazine, 4-aralkylpiperazine and 4-arylpiperazine.
- 33. Method as claimed in claim 32 wherein said sulphonamide compound is selected from
- 4-[2-(4-toluenesulphoamido)-ethyl]-phenylacetic acid;
- 3-[4-(2-benzenesulphonamidoethyl)-phenyl]-propionic acid;
- 4-(2-benzenesulphonamidoethyl)-phenylacetic acid;
- 4-(3-benzenesulphonamidopropyl)-phenylacetic acid; and
- 3-{4-[2-(2,5-dichlorobenzenesulphonamido)-ethyl]-phenyl}-propionic acid.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3000377 |
Jan 1980 |
DEX |
|
Parent Case Info
This is a continuation application U.S. Ser. No. 215,469 filed Dec. 11, 1980, now abandoned.
US Referenced Citations (5)
Continuations (1)
|
Number |
Date |
Country |
Parent |
215469 |
Dec 1980 |
|